ArticleCancer research2025
Oxytocin Receptor Regulates the Hippo/YAP Axis to Drive Hepatocarcinogenesis.
Article in Cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- RIBOTAC-mediated degradation of hsa-microRNA-301a-3p suppresses TNBC bone metastasis.Science advances · 2026Article
- Immunomodulatory crosstalk between GPCR and hippo signaling in cancer: implications for tumor immunity and therapeutic targeting.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Dysregulation of Hippo signaling, especially the downstream effector YAP, is a critical driver of hepatocellular carcinoma (HCC). Therefore, identifying therapeutic targets to block Hippo signaling could help improve survival outcomes for patients with HCC. In this study, we conducted an unbiased siRNA screen on G protein-coupled receptors targeted by drugs approved in the United States and strongly associated with the Hippo/YAP pathway and identified the oxytocin receptor (OXTR) as an important activator of the Hippo/YAP axis in HCC. The OXTR was correlated with the Hippo gene signature and poor survival outcomes in HCC, and OXTR activation promoted HCC progression through the Hippo/YAP axis. The OXTR antagonist atosiban blocked the growth of HCC in xenograft, patient-derived explant, organoid, and MST1/2 double-knockout mouse models. Molecular studies revealed that activation of the OXTR facilitated YAP dephosphorylation, nuclear accumulation, and transcriptional activation in HCC. OXTR interacted with Gαq/11 at several important sites (R137, I141, and I227) and induced YAP activation through the Gαq/11/Rho-associated protein kinase/LATS axis. Chromatin immunoprecipitation assays showed that YAP bound to the enhancer region of the OXTR and facilitated its transcription, creating a positive feedback loop. Together, this study uncovered the interplay between Hippo signaling and the OXTR pathway in hepatocarcinogenesis and established OXTR inhibition with atosiban as a promising strategy for treating HCC. SIGNIFICANCE: The FDA-approved oxytocin receptor antagonist atosiban can ameliorate Hippo signaling dysfunction in liver cancer to suppress tumor growth, providing an effective and rapidly translatable therapy for hepatocellular carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.